Non-interventional Study With Azacitidin (Vidaza®)

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

NCT01074047 ·Status: COMPLETED ·Phase: PHASE3

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

NCT00339196 ·Status: COMPLETED ·Phase: PHASE2

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

NCT04712942 ·Status: COMPLETED ·Phase: PHASE2

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02319135 ·Status: COMPLETED ·Phase: PHASE3

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

NCT00660400 ·Status: COMPLETED ·Phase: NA

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT00666497 ·Status: TERMINATED ·Phase: PHASE2

A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

NCT02303782 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

NCT01460498 ·Status: COMPLETED ·Phase: PHASE1

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

NCT01957644 ·Status: TERMINATED ·Phase: PHASE1

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT01541280 ·Status: COMPLETED ·Phase: PHASE2

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

NCT01065129 ·Status: COMPLETED ·Phase: PHASE1

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

NCT02124174 ·Status: UNKNOWN ·Phase: PHASE2

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

NCT00813124 ·Status: COMPLETED ·Phase: PHASE2

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

NCT02117219 ·Status: COMPLETED ·Phase: PHASE1

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

NCT02610777 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Maintenance With Azacitidine in MDS Patients

NCT00446303 ·Status: TERMINATED ·Phase: PHASE2

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

NCT04602273 ·Status: UNKNOWN

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

NCT04842604 ·Status: COMPLETED ·Phase: PHASE3

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

NCT02204020 ·Status: WITHDRAWN ·Phase: PHASE2

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of AZD9829 in CD123+ Hematological Malignancies

NCT06179511 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

NCT01324960 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

NCT02489929 ·Status: UNKNOWN ·Phase: NA

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

NCT01015352 ·Status: COMPLETED ·Phase: PHASE2